Fred Aslan Biography and Net Worth

President and Chief Executive Officer of Artiva Biotherapeutics

Fred Aslan, M.D., has a 20-year track record as an executive and investor in the life sciences industry. He was most recently President and CBO at Vividion Therapeutics, where he was responsible for business development, finance, alliance and project management, and operations. Dr. Aslan had the opportunity to lead Vividion’s Series B financing and $135M-upfront collaboration with Roche. Prior to Vividion, Dr. Aslan had a 12-year affiliation with Venrock. Initially he was an investor from 2006 to 2013, when he cofounded and served as a board member of Receptos Pharmaceuticals (acquired by Celgene for more than $7 billion). Dr. Aslan led Venrock’s investment in Zeltiq (acquired by Allergan for more than $2 billion) and was involved in the early formation of Fate Therapeutics. Subsequently as an entrepreneur from 2013 to 2018, he was CEO of Adavium Medical, a Brazilian medical device company, which he grew from zero to 350 employees, sales of over US$40 million, and fully integrated R&D, manufacturing, and commercial capabilities. Prior to Venrock, Dr. Aslan was Director of Business Development and Head of Investor Relations for CuraGen, a Nasdaq-listed oncology-focused biotech company. Prior to CuraGen, he was a consultant at Boston Consulting Group (BCG). Dr. Aslan holds a B.S. in biology from Duke University, an M.D. from Yale School of Medicine, and an MBA from Harvard Business School.

What is Fred Aslan's net worth?: The estimated net worth of Fred Aslan is at least $15.26 million as of December 15th, 2025. Dr. Aslan owns 1,209,948 shares of Artiva Biotherapeutics stock worth more than $15,258,654 as of May 6th. This net worth evaluation does not reflect any other investments that Dr. Aslan may own. Learn More about Fred Aslan's net worth.
How do I contact Fred Aslan?: The corporate mailing address for Dr. Aslan and other Artiva Biotherapeutics executives is , , . Artiva Biotherapeutics can also be reached via phone at (858) 267-4467 and via email at [email protected]. Learn More on Fred Aslan's contact information.
Has Fred Aslan been buying or selling shares of Artiva Biotherapeutics?: Fred Aslan has not been actively trading shares of Artiva Biotherapeutics during the last quarter. Most recently, Fred Aslan sold 3,187 shares of the business's stock in a transaction on Monday, December 15th. The shares were sold at an average price of $6.00, for a transaction totalling $19,122.00. Following the completion of the sale, the chief executive officer now directly owns 1,209,948 shares of the company's stock, valued at $7,259,688. Learn More on Fred Aslan's trading history.
Are insiders buying or selling shares of Artiva Biotherapeutics?: In the last year, insiders at the sold shares 4 times. They sold a total of 60,562 shares worth more than $263,284.50. The most recent insider tranaction occured on December, 15th when CEO Fred Aslan sold 3,187 shares worth more than $19,122.00. Insiders at Artiva Biotherapeutics own 21.4% of the company. Learn More about insider trades at Artiva Biotherapeutics.
Information on this page was last updated on 12/15/2025.

Fred Aslan Insider Trading History at Artiva Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/15/2025	Sell	3,187	$6.00	$19,122.00	1,209,948
11/17/2025	Sell	6,375	$3.38	$21,547.50	343,999
10/17/2025	Sell	25,500	$6.00	$153,000.00	356,721
8/15/2025	Sell	25,500	$2.73	$69,615.00	386,693

Fred Aslan Buying and Selling Activity at Artiva Biotherapeutics

Artiva Biotherapeutics Company Overview

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Today's Range

Now: $12.48

$11.00

$13.00

50 Day Range

MA: $7.29

$4.80

$13.39

2 Week Range

Now: $12.48

$1.47

$14.53

Volume

229,683 shs

Average Volume

224,947 shs

Market Capitalization

$308.38 million

P/E Ratio

N/A

Dividend Yield